Cargando…
Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy
Treating breast cancer brain metastases (BCBMs) is challenging. Na(+)/I(−) symporter (NIS) expression in BCBMs would permit their selective targeting with radioiodide ((131)I(−)). We show impressive enhancement of tumor response by combining(131)I(−) with gemcitabine (GEM), a cytotoxic radiosensitiz...
Autores principales: | Renier, Corinne, Do, John, Reyna-Neyra, Andrea, Foster, Deshka, De, Abhijit, Vogel, Hannes, Jeffrey, Stefanie S., Tse, Victor, Carrasco, Nancy, Wapnir, Irene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342383/ https://www.ncbi.nlm.nih.gov/pubmed/27363025 http://dx.doi.org/10.18632/oncotarget.10238 |
Ejemplares similares
-
An extremely high dietary iodide supply forestalls severe hypothyroidism in Na(+)/I(−) symporter (NIS) knockout mice
por: Ferrandino, Giuseppe, et al.
Publicado: (2017) -
Expression of the Na(+)/l(- )symporter (NIS) is markedly decreased or absent in gastric cancer and intestinal metaplastic mucosa of Barrett esophagus
por: Altorjay, Áron, et al.
Publicado: (2007) -
Modulation of thyroidal radioiodide uptake by oncological pipeline inhibitors and Apigenin
por: Lakshmanan, Aparna, et al.
Publicado: (2015) -
CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy
por: Ke, Chien-Chih, et al.
Publicado: (2012) -
Implications of Na(+)/I(-) Symporter Transport to the Plasma Membrane for Thyroid Hormonogenesis and Radioiodide Therapy
por: Martín, Mariano, et al.
Publicado: (2018)